Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 47, 2016, Pages 77683-77695

  Wong, Kwong Fai ^a   Liu, Angela M ^a   Hong, Wanjin ^b   Xu, Zhi ^c   Luk, John M ^a,d,e  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c NANJING MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e Arbele Limited   (Hong Kong)

Author keywords

Extracellular stimuli; Hippo pathway; Liver cancer; MST1; Yes associated protein

Indexed keywords

AXL RECEPTOR TYROSINE KINASE; CELL PROTEIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN D1; GLYPICAN 3; LARGE TUMOR SUPPRESSOR HOMOLOG 1; MAMMALIAN STERILE 20 LIKE KINASE 1; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; SRY BOX 4; TRANSCRIPTION FACTOR SOX; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; ALPHA2 INTEGRIN; BETA1 INTEGRIN; CTGF PROTEIN, HUMAN; LATS1 PROTEIN, HUMAN; MAMMALIAN STERILE 20-LIKE KINASE 1, HUMAN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SERINE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER SURVIVAL; CARCINOGENICITY; CELL ADHESION; CONTROLLED STUDY; CTGF GENE; ENZYME ASSAY; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HIPPO SIGNALING PATHWAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; ITGA2 GENE; LIVER CELL CARCINOMA; MALE; ONCOGENIC SIGNALING; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; GENETICS; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; HUMANS; INTEGRIN ALPHA2; INTEGRIN BETA1; LIVER NEOPLASMS; MALE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SERINE; SIGNAL TRANSDUCTION;

EID: 84998672570     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12760     Document Type: Article

References (60)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7-30.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115-132.
3. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, Poon RT, Fan ST, Chan KL, et al. Genomewide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012; 44:765-769.
4. Schwartz M, Roayaie S and Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007; 4:424-432.
5. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S and Lowe SW. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008; 135:852-864.
6. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S and Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006; 125:1253-1267.
7. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130:1120-1133.
8. Grusche FA, Degoutin JL, Richardson HE and Harvey KF. The Salvador/Warts/Hippo pathway controls regenerative tissue growth in Drosophila melanogaster. Dev Biol. 2010; 350:255-266.
9. Liu AM, Wong KF, Jiang X, Qiao Y and Luk JM. Regulators of mammalian Hippo pathway in cancer. Biochim Biophys Acta. 2012; 1826:357-364.
10. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ, Hong W, Zhao S, Xiong Y, Lei QY and Guan KL. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF(beta)-TrCP E3 ligase. J Biol Chem. 2010; 285:37159-37169.
11. Zhao B, Li L, Tumaneng K, Wang CY and Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010; 24:72-85.
12. Yu FX, Zhao B and Guan KL. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015; 163:811-828.
13. Liu AM, Xu Z and Luk JM. An update on targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther Targets. 2012; 16:243-247.
14. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG and Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012; 109:E2441-2450.
15. Kim NG, Koh E, Chen X and Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011; 108:11930-11935.
16. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC and Ma L. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012; 18:1511-1517.
17. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT and Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009; 115:4576-4585.
18. Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng T, Zhu L, Rong Y, Shen H, Luk JM, Zhang X and Qin N. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J. 2014.
19. Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M and Sheetz M. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 2014.
20. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G and Sahai E. Mechanotransduction and YAPdependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013; 15:637-646.
21. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S and Piccolo S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013; 154:1047-1059.
22. Hao J, Zhang Y, Wang Y, Ye R, Qiu J, Zhao Z and Li J. Role of extracellular matrix and YAP/TAZ in cell fate determination. Cell Signal. 2014; 26:186-191.
23. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N and Piccolo S. Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474:179-183.
24. Luk JM and Guan KL. An alternative DNA damage pathway to apoptosis in hematological cancers. Nat Med. 2014; 20:587-588.
25. Nukuda A, Sasaki C, Ishihara S, Mizutani T, Nakamura K, Ayabe T, Kawabata K and Haga H. Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression. Oncogenesis. 2015; 4:e165.
26. Madamanchi A, Santoro SA and Zutter MM. alpha2beta1 Integrin. Adv Exp Med Biol. 2014; 819:41-60.
27. Esposito M and Kang Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther. 2014; 141:222-233.
28. Bartolome RA, Barderas R, Torres S, Fernandez-Acenero MJ, Mendes M, Garcia-Foncillas J, Lopez-Lucendo M and Casal JI. Cadherin-17 interacts with alpha2beta1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis. Oncogene. 2014; 33:1658-1669.
29. Dudley DT, Li XY, Hu CY, Kleer CG, Willis AL and Weiss SJ. A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies. Proc Natl Acad Sci U S A. 2014; 111:14882-14887.
30. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W and Luk JM. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011; 30:1229-1240.
31. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee J-S and Johnson RL. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. 2010; 107:1437-1442.
32. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C and Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem. 2011; 286:7018-7026.
33. Fink J, Carpi N, Betz T, Betard A, Chebah M, Azioune A, Bornens M, Sykes C, Fetler L, Cuvelier D and Piel M. External forces control mitotic spindle positioning. Nat Cell Biol. 2011; 13:771-778.
34. Masumoto A, Arao S and Otsuki M. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells. Hepatology. 1999; 29:68-74.
35. Burnier JV, Wang N, Michel RP, Hassanain M, Li S, Lu Y, Metrakos P, Antecka E, Burnier MN, Ponton A, Gallinger S and Brodt P. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene. 2011; 30:3766-3783.
36. Ho WC, Heinemann C, Hangan D, Uniyal S, Morris VL and Chan BM. Modulation of in vivo migratory function of alpha 2 beta 1 integrin in mouse liver. Mol Biol Cell. 1997; 8:1863-1875.
37. Hangan D, Uniyal S, Morris VL, MacDonald IC, von Ballestrem C, Chau T, Schmidt EE, Chambers AF, Groom AC and Chan BM. Integrin VLA-2 (alpha2beta1) function in postextravasation movement of human rhabdomyosarcoma RD cells in the liver. Cancer Res. 1996; 56:3142-3149.
38. Jaalouk DE and Lammerding J. Mechanotransduction gone awry. Nat Rev Mol Cell Biol. 2009; 10:63-73.
39. Mammoto T and Ingber DE. Mechanical control of tissue and organ development. Development. 2010; 137:1407-1420.
40. Jaalouk DE and Lammerding J. Mechanotransduction gone awry. Nat Rev Mol Cell Biol. 2009; 10:63-73.
41. Vogel V and Sheetz M. Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol. 2006; 7:265-275.
42. Dupont S. Role of YAP/TAZ in cell-matrix adhesionmediated signalling and mechanotransduction. Exp Cell Res. 2015.
43. Serrano I, McDonald PC, Lock F, Muller WJ and Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun. 2013; 4:2976.
44. Bartolome RA, Pelaez-Garcia A, Gomez I, Torres S, Fernandez-Acenero MJ, Escudero-Paniagua B, Imbaud JI and Casal JI. An RGD motif present in cadherin 17 induces integrin activation and tumor growth. J Biol Chem. 2014; 289:34801-34814.
45. Ihara S, Hagedorn EJ, Morrissey MA, Chi Q, Motegi F, Kramer JM and Sherwood DR. Basement membrane sliding and targeted adhesion remodels tissue boundaries during uterine-vulval attachment in Caenorhabditis elegans. Nat Cell Biol. 2011; 13:641-651.
46. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003; 3:422-433.
47. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, Wang CY, Gao B, Jiang J and Yang Y. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A. 2010; 107:1431-1436.
48. Angus L, Moleirinho S, Herron L, Sinha A, Zhang X, Niestrata M, Dholakia K, Prystowsky MB, Harvey KF, Reynolds PA and Gunn-Moore FJ. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene. 2011; 31:238-250.
49. Morinaka A, Funato Y, Uesugi K and Miki H. Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis. Oncogene. 2011; 30:4208-4218.
50. Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q and Pardee AB. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell. 2010; 38:512-523.
51. Ni L, Li S, Yu J, Min J, Brautigam CA, Tomchick DR, Pan D and Luo X. Structural basis for autoactivation of human Mst2 kinase and its regulation by RASSF5. Structure. 2013; 21:1757-1768.
52. Metcalf DG, Moore DT, Wu Y, Kielec JM, Molnar K, Valentine KG, Wand AJ, Bennett JS and DeGrado WF. NMR analysis of the alphaIIb beta3 cytoplasmic interaction suggests a mechanism for integrin regulation. Proc Natl Acad Sci U S A. 2010; 107:22481-22486.
53. Wang Z, Leisner TM and Parise LV. Platelet alpha2beta1 integrin activation: contribution of ligand internalization and the alpha2-cytoplasmic domain. Blood. 2003; 102:1307-1315.
54. Klekotka PA, Santoro SA, Wang H and Zutter MM. Specific residues within the alpha 2 integrin subunit cytoplasmic domain regulate migration and cell cycle progression via distinct MAPK pathways. J Biol Chem. 2001; 276:32353-32361.
55. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 2009; 50:1453-1463.
56. Wong KF, Luk JM, Cheng RH, Klickstein LB and Fan ST. Characterization of two novel LPS-binding sites in leukocyte integrin betaA domain. FASEB J. 2007; 21:3231-3239.
57. Liu AM, Poon RT and Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010; 394:623-627.
58. Zhu R, Wong KF, Lee NP, Lee KF and Luk JM. HNF1alpha and CDX2 transcriptional factors bind to cadherin-17 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. J Cell Biochem. 2010; 111:618-628.
59. Ivanovska I, Zhang C, Liu AM, Wong KF, Lee NP, Lewis P, Philippar U, Bansal D, Buser C, Scott M, Mao M, Poon RT, Fan ST, Cleary MA, Luk JM and Dai H. Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One. 2011; 6:e24582.
60. Lamb JR, Zhang C, Xie T, Wang K, Zhang B, Hao K, Chudin E, Fraser HB, Millstein J, Ferguson M, Suver C, Ivanovska I, Scott M, Philippar U, Bansal D, Zhang Z, et al. Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One. 2011; 6:e20090.